An open-label phase I safety, pharmacokinetic and dosimetry study of 188Re-PTI-6D2 in patients with metastatic melanoma
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2011
At a glance
- Drugs PTI 188 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics
- 03 Feb 2011 Survival results will be presented at the 2011 American Society of Clinical Oncology Meeting, according to a Pain Therapeutics media release.
- 23 Mar 2010 Positive efficacy results evaluating both phase I trials in patients with metastatic melanoma in Israel have been reported in a Pain Therapeutics media release.
- 23 Jun 2008 Top-line results reported in a Pain Therapeutics media release.